Abstract
The effect of dose on the pharmacokinetics of ciprofloxacin in serum and urine following single intravenous doses of 100, 150, and 200 mg was studied in nine healthy volunteers. Mean peak levels in serum were 1.4, 2.0, and 3.2 mg/liter for the 100-, 150-, and 200-mg doses, respectively. The data on concentrations in serum were best described by a three-compartment pharmacokinetic model. The terminal half-life (from noncompartmental analysis) averaged between 4.2 and 4.6 h. Average urinary recovery ranged between 45.8 and 48.1%. The average renal clearance of ciprofloxacin was 2.9- to 3.4-fold greater than the measured creatinine clearance. Total serum and renal clearances decreased with increasing dose; however, this was not statistically significant (P greater than 0.05; repeated-measures analysis of variance). Ciprofloxacin was well tolerated by all subjects. In this dose range, ciprofloxacin pharmacokinetics are independent of dose.
MeSH Terms
Ciprofloxacin/blood,pharmacokinetics
Dose-Response Relationship, Drug
Humans
Injections, Intravenous
Kidney/metabolism
Male
Models, Biological
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Dudley M N
Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston 02881.
Ericson J
Zinner S H
References (14)
14 references, click to expand
-
Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.
J Pharmacokinet Biopharm. 1978 Apr;6(2):165-75
PMID: 671222
-
Pharmacokinetics of intravenously administered ciprofloxacin.
Antimicrob Agents Chemother. 1984 Aug;26(2):208-10
PMID: 6486762
-
Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.
Eur J Clin Microbiol. 1984 Aug;3(4):355-9
PMID: 6489326
-
Dose- and sex-independent disposition of ciprofloxacin.
Eur J Clin Microbiol. 1984 Aug;3(4):363-6
PMID: 6489328
-
Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.
J Pharmacokinet Biopharm. 1984 Oct;12(5):545-58
PMID: 6520748
-
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
Antimicrob Agents Chemother. 1985 Mar;27(3):375-9
PMID: 3158275
-
Dose ranging study and constant infusion evaluation of ciprofloxacin.
Antimicrob Agents Chemother. 1986 Sep;30(3):440-3
PMID: 3777907
-
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.
Antimicrob Agents Chemother. 1985 Oct;28(4):581-6
PMID: 3000292
-
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.
Antimicrob Agents Chemother. 1985 Aug;28(2):235-9
PMID: 2939794
-
Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration.
Eur J Clin Microbiol. 1986 Apr;5(2):179-86
PMID: 2941277
-
Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses.
Eur J Clin Microbiol. 1986 Apr;5(2):187-92
PMID: 2941278
-
Clinical experience with ciprofloxacin in the USA.
Eur J Clin Microbiol. 1986 Apr;5(2):220-5
PMID: 2941286
-
Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses.
Antimicrob Agents Chemother. 1986 Jan;29(1):62-6
PMID: 2942101
-
Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.
J Pharmacokinet Biopharm. 1985 Apr;13(2):185-201
PMID: 4057057